Sara A. Hurvitz, MD, on Evaluating Biomarkers in Triple-Negative Breast Cancer

Posted: Tuesday, January 5, 2021

Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses findings from the ASCENT study, including analyses of biomarkers and whether they may be useful in selecting patients or guiding therapy with sacituzumab govitecan vs chemotherapy for patients with metastatic triple-negative breast cancer.